Arcellx (ACLX) Total Non-Current Liabilities (2021 - 2025)
Arcellx (ACLX) recorded quarterly Total Non-Current Liabilities of $201.6 million in Q4 2025, down 6.28% quarter-over-quarter from $215.1 million in Q3 2025, and down 18.67% on a YoY basis from $247.9 million in Q4 2024.
Arcellx (ACLX) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Arcellx's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $201.6 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 18.67% year-over-year to $201.6 million; the TTM figure through Dec 2025 stood at $201.6 million (down 18.67% YoY), while the FY2025 annual figure was $201.6 million, down 18.67% from the prior year.
- Total Non-Current Liabilities was $201.6 million for Q4 2025 at Arcellx, down from $215.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $267.7 million in Q1 2024 to a low of $16.7 million in Q4 2021.
- Historically, Total Non-Current Liabilities has averaged $179.3 million across 4 years, with a median of $226.9 million in 2025.
- Biggest YoY gain for Total Non-Current Liabilities was 2.32% in 2025; the steepest drop was 19.38% in 2025.
- A 4-year view of Total Non-Current Liabilities shows it stood at $16.7 million in 2021, then surged by 204.22% to $50.9 million in 2022, then soared by 386.86% to $247.9 million in 2024, then declined by 18.67% to $201.6 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $201.6 million (Q4 2025), $215.1 million (Q3 2025), and $226.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 201.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 201.64 Mn |
| Sep 30, 2025 | 215.14 Mn |
| Jun 30, 2025 | 226.86 Mn |
| Mar 31, 2025 | 227.74 Mn |
| Dec 31, 2024 | 247.94 Mn |
| Sep 30, 2024 | 266.84 Mn |
| Jun 30, 2024 | 232.24 Mn |
| Mar 31, 2024 | 267.65 Mn |
| Jun 30, 2022 | 50.93 Mn |
| Mar 31, 2022 | 18.90 Mn |
| Dec 31, 2021 | 16.74 Mn |